Decreasing Time-Trends of Colorectal Cancer in a Large Cohort of Patients With Inflammatory Bowel Disease
Background & Aims
Inflammatory bowel disease (IBD) is a risk factor for colorectal cancer (CRC). There have been marked changes in the management and treatment of IBD over the past decades, but little is known about how these changes have impacted morbidity and mortality (time trends in risk) of CRC in patients with IBD.
Methods
We assessed cancer occurrence and mortality in a large population-based cohort of patients with IBD who were diagnosed from 1954 to 1989 (n = 7607). Through register links, we collected data on vital status of all registered cases of CRC, as well as intestinal surgeries and mortalities from CRC through 2004. Relative risks for CRC incidence and mortality, by calendar period of follow-up evaluation, were assessed within the cohort (using Poisson regression and taking age, sex, extent of IBD, and time since IBD diagnosis into account) and also compared with the general population using standardized incidence and mortality ratios.
Results
During 198,227 person-years of follow-up evaluation for the 7607 patients with IBD, 188 new cases of CRC were observed (crude incidence, 95 per 100,000; 95% confidence interval, 82–109); 92 deaths from CRC were registered. Within the IBD cohort, as well as vs the general population, the incidence of CRC showed a tendency towards a decline whereas the mortality from CRC decreased several-fold from the 1960s through 2004.
Conclusions
Over the past 35 years, the risk of diagnosis of CRC in patients with IBD has not declined significantly, but the risk of dying of CRC has decreased substantially.
Abbreviations used in this paper: CI, confidence interval, CRC, colorectal cancer
To access this article, please choose from the options below
This article has an accompanying continuing medical education activity on page 1818. Learning Objective: Upon completion of this CME exam successful learners will be able to discuss different risk estimates for CRC incidence and mortality in IBD.
Conflict of interest The authors disclose no conflicts.
Funding This study was supported by the Swedish Medical Association and the Swedish Cancer Society.
PII: S0016-5085(09)00168-1
doi:10.1053/j.gastro.2009.01.064
© 2009 AGA Institute. Published by Elsevier Inc. All rights reserved.
Refers to article:
- Continuing Medical Education Exam 1, May 2009

